Author:
Fang Chongye,Hayashi Shuhei,Du Xiaocui,Cai Xianbin,Deng Bin,Zheng Hongmei,Ishido Satoshi,Tsutsui Hiroko,Sheng Jun
Abstract
AbstractExercise prevents depression through peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α)-mediated activation of a particular branch of the kynurenine pathway. From kynurenine (KYN), two independent metabolic pathways produce neurofunctionally different metabolites, mainly in somatic organs: neurotoxic intermediate metabolites via main pathway and neuroprotective end product, kynurenic acid (KYNA) via the branch. Elevated levels of KYN have been found in patients with depression. Herein, we investigated whether and how caffeine prevents depression, focusing on the kynurenine pathway. Mice exposed to chronic mild stress (CMS) exhibited depressive-like behaviours with an increase and decrease in plasma levels of pro-neurotoxic KYN and neuroprotective KYNA, respectively. However, caffeine rescued CMS-exposed mice from depressive-like behaviours and restored the plasma levels of KYN and KYNA. Concomitantly, caffeine induced a key enzyme converting KYN into KYNA, namely kynurenine aminotransferase-1 (KAT1), in murine skeletal muscle. Upon caffeine stimulation murine myotubes exhibited KAT1 induction and its upstream PGC-1α sustainment. Furthermore, a proteasome inhibitor, but not translational inhibitor, impeded caffeine sustainment of PGC-1α, suggesting that caffeine induced KAT1 by inhibiting proteasomal degradation of PGC-1α. Thus, caffeine protection against CMS-induced depression may be associated with sustainment of PGC-1α levels and the resultant KAT1 induction in skeletal muscle, and thereby consumption of pro-neurotoxic KYN.
Funder
Yunnan Provincial Joint Project of Basic Agricultural Research
Yunnan Provincial Department of Education Foundation
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Bromet, E. et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 9, 90 (2011).
2. Lim, G. Y. et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci. Rep. 8, 2861 (2018).
3. Fava, M. Management of nonresponse and intolerance: Switching strategies. J. Clin. Psychiatry 61(Suppl 2), 10–12 (2000).
4. John Rush, A. et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354, 1231–1242 (2006).
5. Crown, W. H. et al. The impact of treatment-resistant depression on health care utilization and costs. J. Clin. Psychiatry 63, 963–971 (2002).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献